PubMed Health⌕ Search

PubMed · 10882216

Relapsing polychondritis.

Abstract

Relapsing polychondritis is a rare inflammatory disease of unknown aetiology characterized by recurrent inflammation and destruction of cartilaginous structures and connective tissue. Current data provide increasing support for an autoimmune basis, but its cause remains unknown. Individuals of any race, gender, or age may be affected, but it is most commonly seen between the ages of 40 and 60 years. Although relapsing polychondritis occurs predominantly as a separately defined clinical complex, a significant number of patients may suffer from another underlying rheumatic and/or haematological disorder; vasculitic syndromes are the most commonly observed disorders associated with relapsing polychondritis. Common clinical features are auricular, nasal and respiratory tract chondritis with involvement of organs of special sense, such as the eyes and audiovestibular apparatus. Polyarthritis and vasculitic involvement are also common. Corticosteroids are still the agents of choice although several other anti-inflammatory drugs can be used in order to allow tapering of the steroid dose or to achieve a lower maintenance dose for refractory cases.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J F Molina, L R Espinoza. 2000. Relapsing polychondritis.. https://doi.org/10.1053/berh.1999.0079

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Simultaneous viral infection and childhood bronchiolitis obliterans.

Lower respiratory tract infections by respiratory syncytial virus (RSV) are frequent in childhood. Association of RSV with bronchiolitis obliterans has rarely been established. We report a 13-month-old child with bronchiolitis obliterans following co-infection by RSV and adenovirus, and suggest that complicated evolution of an acute bronchiolitis case can indicate an association of pathogens.

Adrenal Cortex Hormones↗

Cost-efficacy analysis of ondansetron regimens for control of emesis induced by noncisplatin, moderately emetogenic chemotherapy.

The cost efficacy of various ondansetron regimens for the control of emesis induced by noncisplatin, moderately emetogenic chemotherapy was examined from a hospital perspective. Previous cost-efficacy analyses of ondansetron provide limited insight into the economic impact of ondansetron when used with moderately emetogenic chemotherapies. Clinical efficacy results of trials that used ondansetron to control emesis were retrieved from the biomedical literature published between January 1966 and December 2000. Only direct antiemetic treatment costs were considered. A total of 55 trials were analyzed, with a total of 22 regimens identified. Costs of antiemetic treatments were calculated by multiplying the milligrams of each product by the cost per milligram. For each injectable dose, the average cost of an administration device was Can$1.28. Pharmacy time required for preparing an i.v. dose was 2.5 minutes, at an average hourly rate of Can$25. Nursing time to administer each i.v. dose was estimated at one minute at an average rate of Can$23 per hour. The efficacy rate of the 22 regimens varied between 24.2% and 90.4%, while the cost varied from Can$20 to Can$413. A cost-efficacy analysis of ondansetron regimens for control of emesis caused by noncisplatin, moderately emetic antineoplastic treatment revealed regimens that should be avoided as well as regimens that are, in comparison, at least as efficacious and less expensive. The analysis supported the concomitant use of a corticosteroid, twice-daily administration of ondansetron, and limitation of ondansetron administration to a period not exceeding four days.

Adrenal Cortex Hormones↗